375 related articles for article (PubMed ID: 34437586)
1. Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
Toral KJ; Wuenschel MA; Black EP
PLoS One; 2021; 16(8):e0256416. PubMed ID: 34437586
[TBL] [Abstract][Full Text] [Related]
2. MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells.
Stutvoet TS; Kol A; de Vries EG; de Bruyn M; Fehrmann RS; Terwisscha van Scheltinga AG; de Jong S
J Pathol; 2019 Sep; 249(1):52-64. PubMed ID: 30972766
[TBL] [Abstract][Full Text] [Related]
3. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
4. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the programmed death-ligand 1 mRNA expression and immunopositivity and their correlation with survival outcomes in Indian lung cancer patients.
Kumar S; Pandey M; Mir IA; Mukhopadhyay A; Sharawat SK; Jain D; Saikia J; Malik PS; Kumar S; Mohan A
Hum Cell; 2022 Jan; 35(1):286-298. PubMed ID: 34786661
[TBL] [Abstract][Full Text] [Related]
6. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.
Della Corte CM; Ciaramella V; Ramkumar K; Vicidomini G; Fiorelli A; Nardone V; Cappabianca S; Cozzolino I; Zito Marino F; Di Guida G; Wang Q; Cardnell R; Gay CM; Ciardiello D; Martinelli E; Troiani T; Martini G; Napolitano S; Wang J; Byers LA; Ciardiello F; Morgillo F
J Transl Med; 2022 Nov; 20(1):541. PubMed ID: 36419183
[TBL] [Abstract][Full Text] [Related]
7. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
[TBL] [Abstract][Full Text] [Related]
8. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
9. Programmed death-ligand 1 expression in non-small cell lung carcinoma - mechanism of regulation, association with other markers, and therapeutic implication.
Tancoš V; Blichárová A; Plank L
Klin Onkol; 2022; 35(5):372-376. PubMed ID: 36443097
[TBL] [Abstract][Full Text] [Related]
10. A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer.
Han Y; Liu SM; Jin R; Meng W; Wu YL; Li H
Front Immunol; 2023; 14():1178193. PubMed ID: 37492578
[TBL] [Abstract][Full Text] [Related]
11. High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancer.
Feng HB; Chen Y; Xie Z; Jiang J; Zhong YM; Guo WB; Yan WQ; Lv ZY; Lu DX; Liang HL; Xu FP; Yang JJ; Yang XN; Zhou Q; Zhang DK; Zhang Z; Chuai SK; Zhang HH; Wu YL; Zhang XC
Thorac Cancer; 2021 Oct; 12(19):2564-2573. PubMed ID: 34490728
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice.
Eguren-Santamaria I; Sanmamed MF; Goldberg SB; Kluger HM; Idoate MA; Lu BY; Corral J; Schalper KA; Herbst RS; Gil-Bazo I
Clin Cancer Res; 2020 Aug; 26(16):4186-4197. PubMed ID: 32354698
[TBL] [Abstract][Full Text] [Related]
13. Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer.
Murugesan K; Jin DX; Comment LA; Fabrizio D; Hegde PS; Elvin JA; Alexander B; Levy MA; Frampton GM; Montesion M; Roychowdhury S; Kurzrock R; Ross JS; Albacker LA; Huang RSP
Oncologist; 2022 Sep; 27(9):732-739. PubMed ID: 35598202
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
[No Abstract] [Full Text] [Related]
15. PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).
Jiang L; Su X; Zhang T; Yin X; Zhang M; Fu H; Han H; Sun Y; Dong L; Qian J; Xu Y; Fu X; Gavine PR; Zhou Y; Tian K; Huang J; Shen D; Jiang H; Yao Y; Han B; Gu Y
Oncotarget; 2017 Apr; 8(16):26845-26857. PubMed ID: 28460468
[TBL] [Abstract][Full Text] [Related]
16. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
17. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
[TBL] [Abstract][Full Text] [Related]
18. HYR-2 plays an anti-lung cancer role by regulating PD-L1 and Akkermansia muciniphila.
Teng L; Wang K; Chen W; Wang YS; Bi L
Pharmacol Res; 2020 Oct; 160():105086. PubMed ID: 32687951
[TBL] [Abstract][Full Text] [Related]
19. A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC.
Chen M; Lu H; Copley SJ; Han Y; Logan A; Viola P; Cortellini A; Pinato DJ; Power D; Aboagye EO
J Thorac Oncol; 2023 Jun; 18(6):718-730. PubMed ID: 36773776
[TBL] [Abstract][Full Text] [Related]
20. Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
Uruga H; Mino-Kenudson M
Virchows Arch; 2021 Jan; 478(1):31-44. PubMed ID: 33486574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
